About Creatine kinase S-type, mitochondrial
Creatine kinase S-type, mitochondrial (CKMT2) is a protein
from Homo sapiens identified by UniProt accession
P17540, 419 residues long.
MolForge cross-references it against 0 known binders and
112 disease associations.
Target properties
| Protein name | Creatine kinase S-type, mitochondrial |
| UniProt accession | P17540 |
| Gene | CKMT2 |
| Organism | Homo sapiens |
| Length | 419 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (112)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.18
- Parkinson disease · score 0.18
- multiple sclerosis · score 0.18
- Alzheimer disease · score 0.18
- lysosomal storage disease · score 0.18
- genetic disorder · score 0.12
- protein measurement · score 0.10
- cancer · score 0.08
- hypertrophic cardiomyopathy · score 0.07
- familial atrial fibrillation · score 0.05
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P17540-F1 | alphafold | PREDICTED | 89.41 | — |
Amino-acid sequence (419 residues)
MASIFSKLLT GRNASLLFAT MGTSVLTTGY LLNRQKVCAE VREQPRLFPP SADYPDLRKH NNCMAECLTP AIYAKLRNKV TPNGYTLDQC IQTGVDNPGH PFIKTVGMVA GDEESYEVFA DLFDPVIKLR HNGYDPRVMK HTTDLDASKI TQGQFDEHYV LSSRVRTGRS IRGLSLPPAC TRAERREVEN VAITALEGLK GDLAGRYYKL SEMTEQDQQR LIDDHFLFDK PVSPLLTCAG MARDWPDARG IWHNYDKTFL IWINEEDHTR VISMEKGGNM KRVFERFCRG LKEVERLIQE RGWEFMWNER LGYILTCPSN LGTGLRAGVH VRIPKLSKDP RFSKILENLR LQKRGTGGVD TAAVADVYDI SNIDRIGRSE VELVQIVIDG VNYLVDCEKK LERGQDIKVP PPLPQFGKK
Explore Creatine kinase S-type, mitochondrial with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets